Abstract: The present disclosure provides anti-nucleolin antibodies, methods of producing anti-nucleolin antibodies, and cells producing anti-nucleolin antibodies. Also provided are methods of using anti-nucleolin antibodies in treating malignant and non-malignant diseases.

Abstract: A device for measuring eye movement in a human subject comprises a housing, at least one stimulator mounted to the housing, and a sensor. The at least one stimulator is configured to provide stimulus to one or both eyes of the subject. The sensor is configured to collect information related to movement of one or both eyes of the subject. The device also includes a user interface that is configured to control the at least one stimulator and display information collected by the camera.

Abstract: An expandable vertebral body device, system, instrument, and methods of assembly and using the device, system, and instrument are disclosed. The vertebral body device includes a body with a first end and a second end, a first rotating member rotatably coupled to the first end, a second rotating member rotatably coupled to the second end, a first extension member moveably coupled to the first end, and a second extension member moveably coupled to the second end. The expandable cage system comprises a vertebral body device and an insertion instrument. Methods for assembling and using the vertebral body device and instrument are also disclosed.

Abstract: An expandable vertebral body implant, and methods of assembly and using the implant. The vertebral body implant includes a body with a first end and a second end, a rotating member rotatably coupled to the first end of the body, wherein an end includes a plurality of first notches inset into the rotating member, an extension member moveably coupled to the rotating member, and a locking member positioned on an interior of the body. Methods for assembling and using the vertebral body implant are also disclosed.

Abstract: A system for reducing toxicity from intravascular triggered drug delivery includes a chamber comprising an inflow port, an outflow port, and a filter positioned upstream of the outflow port. A trigger module is configured to trigger the release of a drug from an intravascular triggered drug delivery system present in blood in the chamber. A method for reducing toxicity from intravascular triggered drug delivery includes the steps of removing blood comprising an intravascular triggered drug delivery system from a patient's vascular system and delivering the blood to a chamber, applying a trigger to the blood to release a drug from the intravascular triggered drug delivery system, filtering the drug from the blood, and returning the filtered blood to the patient.

Abstract: The present invention relates to systems for providing noninvasive cranial nerve stimulation and methods for using the same. The present invention administers therapy through electrodes that are noninvasively attached to one or more of a subject's cranial nerve. The systems can be used to enhancing rehabilitation and recovery by improving neuroplasticity and coupling muscle training with feedback.

Abstract: Methods and monodisperse glass microsphere composites comprising a porous wall hollow-glass microsphere; a cargo of a therapeutic is loaded inside of the porous wall hollow-glass microsphere; and a first shell fully encapsulating the porous wall hollow-glass microsphere and capping pores in the walls, retaining the cargo inside of the porous wall hollow-glass microsphere.

Abstract: A cranial anchor system configured to attach to an opening in a cranium includes an anchor member. The anchor member has a middle anchor portion and a lower anchor portion coupled to and disposed in a downward direction relative to the middle anchor portion. The lower anchor portion has a plurality of contact members, each of which have a leg that extends at least partially in the downward direction, a tab connected to the leg, and a rib disposed between the leg and the tab. The system further includes an outer sheath and an inner sheath disposed within the outer sheath and slidable relative to the outer sheath.

Abstract: The present disclosure provides methods for the treatment or prevention of SARS-Cov-2 infection or disease and IL-6 mediated immune/autoimmune and cancers by the administration of GSNO or GSNO reductase inhibitor.

Abstract: The present disclosure provides anti-nucleolin antibodies, methods of producing anti-nucleolin antibodies, and cells producing anti-nucleolin antibodies. Also provided are methods of using anti-nucleolin antibodies in treating malignant and non-malignant diseases.

Abstract: Provided herein is a formulation to pre-treat an organ prior to transplantation and for inducing mitochondrial morphological alterations.

Abstract: Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4-naphthoquinones.

Abstract: Provided herein is a formulation to pre-treat an organ prior to transplantation, comprising a therapeutically effective amount of an immunosuppressive agent encapsulated in a micelle, liposome or polymeric nanoparticle that comprises on its surface a targeting moiety.

Abstract: Systems and methods for detecting metal clips inserted within a portion of a body of a patient are disclosed herein. In one embodiment, a clip detector assembly includes a detector having a ferrous member, a transmitting coil around the ferrous member and configured to induce a current in the metal clip, and a receiving coil around the ferrous member and configured to receive a magnetic field generated by the current induced in the metal clip. The assembly can further include a control circuit having a band-pass filter configured to pass electrical signals induced by the magnetic field from the receiving coil that are within at most 35 kHz of a resonance frequency of the metal clip. The assembly still further includes a user notification component configured to alert a user to a location of the metal clip.

Abstract: Cells, such a T-cells, are provided that comprise cytokine receptors having increased activity in response to their ligand. For example, cell can comprise IL-2 and/or IL-15 receptors having increased surface expression or signaling activity. Cells of the embodiments have a significant growth advantage in the presence of cytokines and can be used, e.g., for enhanced adoptive cell transfer therapies.

Abstract: Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.

Abstract: Provided herein are surgical guides with internal channels for irrigation cooling. In one embodiment, an apparatus for guiding a surgical instrument includes a proximal side and a distal side. A first channel is configured to guide a material removal device, where the first channel extends from the proximal side of the apparatus to the distal side of the apparatus. A second channel configured to direct irrigation fluid, where the second channel extends from the proximal side of the of the apparatus to the distal side of the apparatus. The first channel is separate from the second channel. A method of performing a surgical procedure and a method of manufacturing a surgical guide are also disclosed. In certain embodiments, the surgical guides may be manufactured via additive manufacturing processes, including for example, three-dimensional printing processes.

Abstract: Provided herein, inter alia, are compositions and methods of using the same for detecting complement activation.

Abstract: The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.

Abstract: The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both.